ISPOR 19th ANNUAL INTERNATIONAL MEETING AWARDS WINNERS

The ISPOR Research Presentation Podium and Poster Awards were established in 1998 to recognize the scientific merit of podium and poster presentations of the ISPOR Annual International Meetings, Annual European Congresses, Asia-Pacific and Latin America Conferences.

This year, the ISPOR judges evaluated podium presentations and nominated poster presentations. All podium presentations are considered for an award. Poster presentations in the top 10%, based on abstract review score, are considered and eligible for a poster presentation award.
Evaluations of scientific merit were based upon the following criteria:

  • Background provides appropriate perspective / context for the subject
  • Objectives / research questions are clearly stated
  • Research design / methods / modeling is appropriate and transparent (scores on this will determine winners in case of ties)
  • Data sources and/or sampling procedures are clear and appropriate
  • Data analyses are appropriate
  • Research objectives are met/addressed
  • Implications of findings are discussed
  • Factual information is kept separate from interpretations or implications
  • Abstract is presented in an unbiased manner
  • Clarity of presentation

THE RECIPIENTS ARE: . . .

ISPOR Best Podium Research Presentation Awards

Best General Podium Presentations

HT1-ALIGNED AND FLEXIBLE? A COMPARATIVE REVIEW OF SMC AND NICE DECISION-MAKING
Johnson H1, Spoors J2, Johnson J1
1Helen Johnson Consulting Ltd, Welwyn Garden City, UK, 2RJW & Partners, Royston, UK

AD3-MEDICATION ADHERENCE AND PERSISTANCE IN TYPE 2 DIABETES MELLITUS (T2DM): PATIENTS PERSPECTIVE IN THE SPANISH HEALTH CARE SYSTEM
Labrador Barba E1, Hernandez Mijares A2, Alonso Moreno FJ3, Rodriguez de Miguel M1, Orera Peña ML1, Aceituno Mata S4, Perez L4, Faus Dader MJ5
1Mylan, Barcelona, Spain, 2Dr. Peset Hospital, Valencia, Spain, 3Sillería Health Center, Toledo, Spain, 4Outcomes’10, Castellon, Spain, 5Faculty of Pharmacy, Granada, Spain

A patient-centered research about the factors and strategies which diabetes patients consider important for their treatment adherence. Our results could help health professionals to improve poor adherence management by the incorporation of patients’ opinions and preferences.

DB1-MORTALITY EXCESS DUE TO CLOSTRIDIUM DIFFICILE INFECTION - A NATIONAL DATABASE ANALYSIS
Bouee S1, Levy Bachelot L2, Ravonimbola H2, Longepierre L1, Godard C2, Gourmelen J3, Barbut F4 1CEMKA, Bourg La Reine, France, 2MSD France, Courbevoie, France, 3UMS 011 - Inserm - UVSQ, Villejuif, France, 4Laboratory for Clostridium Difficile, Paris, France


Best Student Podium Research Presentations

ND1-BURDEN AND WORK PRODUCTIVITY LOSS IMPAIRMENT FROM PROVIDING CARE TO ALZHEIMER'S DISEASE PATIENTS
Hu X1, Ritchie C2, Wood R3, Jones E3, Black CM4, Khandker RK4, Ambegaonkar BM4
1University of Southern California, Los Angeles, CA, USA, 2University of Edinburgh, Edinburgh, UK, 3Adelphi Real World, Bollington, UK, 4Merck & Co., Inc., Rahway, NJ, USA

PP1-NINE TESTS FOR ASSESING VALIDITY OF A DISCRETE-CHOICE EXPERIMENT
Janssen EM, Bridges JF
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

DB4-USE OF DATA-MINING TO PERFORM A REAL WORLD COST ANALYSIS OF HER2-POSITIVE BREAST CANCER IN IRAN
Ansaripour A1, Zendehdel K2, Tadayon N3, Sadeghi F4, Uyl-de Groot C5, Redekop WK6
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Tehran Medical Sciences and Medical Education University, Tehran, Iran, 3Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of), 4Tehran Medical Sciences and Medical education University, Tehran, Iran, 5National Health Care Institute, Diemen, The Netherlands, 6National University of Singapore, Singapore, Singapore

Best New Investigator Podium Research Presentations

HT6-CRITERIA DRIVING VALUES ASSESSMENTS IN MULTIPLE SCLEROSIS MEDICINES
Visintin E1, Kanavos P2
1London School of Economics and Political Sciences, London, UK, 2London School of Economics and Political Science, London, UK

EE2-IS IT REALLY COST-EFFECTIVE TO RISK-ASSESS ALL HOSPITALIZED PATIENTS FOR PRESSURE ULCERS EVERY NURSING-SHIFT?
Padula WV1, Onyekwere U1, Makic MB2, Wald HL2, Epstein Z3, Meltzer DO4
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2University of Colorado, Aurora, CO, USA, 3Pomona College, Claremont, CA, USA, 4University of Chicago, Chicago, IL, USA

PP3-PATIENTS' PREFERENCES FOR CHARACTERISTICS OF PERIODONTAL DISEASE AND ITS' TREATMENT: A DISCRETE CHOICE EXPERIMENT
Vennedey V1, Danner M1, Civello D1, Schwalm A2, Seidl A2, Hiligsmann M3, Stock S1
1University Hospital Cologne, Cologne, Germany, 2Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, 3Maastricht University, Maastricht, The Netherlands


ISPOR Best Poster Research Presentation Awards

Best General Poster Research Presentations

PRM143-QUALITY OF LIFE OF PATIENTS TREATED FOR MULTIPLE MYELOMA (MM) IN FRANCE IN A REAL-WORLD SETTING
Despiegel N1, Touboul C2, Flinois A2, Saba G2, Gonzalez-McQuire S 3, Suzan F3, Blachier-Poisson C1, Guilhaume C1
1Amgen France, Paris, France, 2Kantar Health, Paris, France, 3Amgen (Europe) GmbH, Zug, Switzerland

This study aims at measuring the health related quality of life in multiple myeloma in the real life setting. It shows that quality of life worsens with disease progression especially when patients are treated with best supportive care. This study is very important to confirm the high burden of multiple myeloma from a patient perspective.

PGI8-RATE AND HEALTHCARE UTILIZATION (LOS AND COSTS) OF ADHESION RELATED COMPLICATIONS AFTER COLON RESECTION PROCEDURES
Etter K1, Sutton N2, Wei D3, Yoo A1
1Johnson & Johnson Co., New Brunswick, NJ, USA, 2Johnson & Johnson Medical Devices, Somerville, NJ, USA, 3Johnson & Johnson Co., Raleigh, NC, USA

This study utilized Truven MarketScan® Commercial and Medicare (2009 to 2013) data to explore adhesion related complications (ARC) within one year after colon resection procedures, with a focus on ARC incidence and associated economic burden.

PSY69-COST-EFFECTIVENESS ANALYSIS OF IBRUTINIB FOR WALDENSTRÖM MACROGLOBULINEMIA IN ITALY
Aiello A1, D'Ausilio A1, Randon F2, Lo Muto R2
1Creativ Ceutical, Milano, Italy, 2Janssen-Cilag, Cologno Monzese, Italy

Best Student Poster Research Presentations

PMH48-FEASIBILITY, RELIABILITY AND VALIDITY OF THE DECISION TOOL UNIPOLAR DEPRESSION (DTUD) IN IDENTIFYING PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN NEED OF HIGHLY SPECIALIZED CARE
van Krugten FC1, Kaddouri M1, Goorden M1, van Balkom AJ2, Ruhé HG3, van Schaik DJ2, van Oppen P2, Hakkaart-van Roijen L1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2VU University Medical Centre, Amsterdam, The Netherlands, 3University Medical Centre Groningen, Groningen, The Netherlands

The focus in this presentation is on the psychometric properties of a tool for the early identification of patients with MDD in need of highly specialized care.

PHP96-COST OF LOST PRODUCTIVITY DUE TO PREMATURE, SUICIDE-RELATED MORTALITY IN POLAND Orlewska K
Medical University of Warsaw, Warsaw, Poland

PMS43-A COST-EFFECTIVENESS ANALYSIS OF ABATACEPT, TOCILIZUMAB, AND TNF-INHIBITOR COMPARED WITH RITUXIMAB AS A SECOND-LINE THERAPY FOR TREATMENT OF RHEUMATOID ARTHRITIS
Huoponen S1, Aaltonen KJ1, Joensuu JT1, Rutanen J2, Relas H3, Taimen K4, Puolakka K5, Sokka T6, Nordström D3, Blom M1
1University of Helsinki, Helsinki, Finland, 2Lahti Central Hospital, Lahti, Finland, 3Helsinki University Central Hospital, Helsinki, Finland, 4Turku University Central Hospital, Turku, Finland, 5South Karelia Central Hospital, Lappeenranta, Finland, 6Jyväskylä Central Hospital, Jyväskylä, Finland

This patient-level simulation model evaluated the cost-effectiveness of abatacept, tocilizumab, and TNF-inhibitors in comparison to rituximab as a second-line biologic therapy in rheumatoid arthritis using the Finnish registry data.

Best New Investigator Poster Research Presentations

PDB92-CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON BASAL INSULIN REGIMENS: RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORD DATA
Lee LK1, Liebert R2, Hallissey B3
1Kantar Health, Foster City, CA, USA, 2Kantar Health, New York, NY, USA, 3Kantar Health, Horsham, PA, USA

PCN157-ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT OF WOMEN WITH HER2-POSITIVE, LOCALLY ADVANCED, INFLAMMATORY OR EARLY BREAST CANCER IN PORTUGAL
Ribeiro I1, Lourenço O2, Alves C1, Thuresson P3, Monteiro I4, Batel-Marques F1
1AIBILI, Coimbra, Portugal, 2University of Coimbra, Coimbra, Portugal, 3F. Hoffmann-La Roche Ltd., Basel, Switzerland, 4Roche Farmacêutica Química, Lda, Amadora, Portugal

PHS141-THE INCREASING IMPORTANCE OF A CONTINENCE NURSE SPECIALIST TO IMPROVE OUTCOMES AND SAVE COSTS OF URINARY INCONTINENCE CARE: AN ANALYSIS OF FUTURE POLICY SCENARIOS
Los J, Corro-Ramos I, Franken M, Al M
Erasmus University Rotterdam, Rotterdam, The Netherlands

ISPOR would like to thank all the judges who have volunteered their time and efforts during the meeting to score podium and poster research presentations.

 

Return to ISPOR Awards Index Page